JP6876680B2 - ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント - Google Patents

ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント Download PDF

Info

Publication number
JP6876680B2
JP6876680B2 JP2018510109A JP2018510109A JP6876680B2 JP 6876680 B2 JP6876680 B2 JP 6876680B2 JP 2018510109 A JP2018510109 A JP 2018510109A JP 2018510109 A JP2018510109 A JP 2018510109A JP 6876680 B2 JP6876680 B2 JP 6876680B2
Authority
JP
Japan
Prior art keywords
sf3b1
cancer
splicing
seq
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018510109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525994A5 (https=
JP2018525994A (ja
Inventor
リーファ ユー，
リーファ ユー，
キアン， ヒュ リム，
キアン， ヒュ リム，
ジャコブ， ディー． フィアラ，
ジャコブ， ディー． フィアラ，
シルヴィア ブオナミーチ，
シルヴィア ブオナミーチ，
佳治 水井
佳治 水井
ピーター， ジー． スミス，
ピーター， ジー． スミス，
ピン ズー，
ピン ズー，
ユニス， サン パク，
ユニス， サン パク，
マイケル， ダブリュー． セイラー，
マイケル， ダブリュー． セイラー，
マルコ， ピーター フェッケス，
マルコ， ピーター フェッケス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2018525994A publication Critical patent/JP2018525994A/ja
Publication of JP2018525994A5 publication Critical patent/JP2018525994A5/ja
Priority to JP2021074145A priority Critical patent/JP7256840B2/ja
Application granted granted Critical
Publication of JP6876680B2 publication Critical patent/JP6876680B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2018510109A 2015-09-01 2016-08-30 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント Active JP6876680B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021074145A JP7256840B2 (ja) 2015-09-01 2021-04-26 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562212876P 2015-09-01 2015-09-01
US62/212,876 2015-09-01
PCT/US2016/049490 WO2017040526A2 (en) 2015-09-01 2016-08-30 Splice variants associated with neomorphic sf3b1 mutants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021074145A Division JP7256840B2 (ja) 2015-09-01 2021-04-26 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント

Publications (3)

Publication Number Publication Date
JP2018525994A JP2018525994A (ja) 2018-09-13
JP2018525994A5 JP2018525994A5 (https=) 2019-10-10
JP6876680B2 true JP6876680B2 (ja) 2021-05-26

Family

ID=56936518

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018510109A Active JP6876680B2 (ja) 2015-09-01 2016-08-30 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント
JP2021074145A Active JP7256840B2 (ja) 2015-09-01 2021-04-26 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021074145A Active JP7256840B2 (ja) 2015-09-01 2021-04-26 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント

Country Status (5)

Country Link
US (2) US10889866B2 (https=)
EP (2) EP3910073B1 (https=)
JP (2) JP6876680B2 (https=)
ES (1) ES2887201T3 (https=)
WO (1) WO2017040526A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2887201T3 (es) 2015-09-01 2021-12-22 Eisai R&D Man Co Ltd Variantes de empalme asociadas con mutantes neomórficos de SF3B1
SG11201907887SA (en) * 2017-03-15 2019-09-27 Eisai Co Ltd Spliceosome mutations and uses thereof
EP3662064A4 (en) * 2017-07-31 2021-07-28 The Johns Hopkins University COMPOSITIONS AND METHODS OF TARGETING MASAS FOR THE TREATMENT OF CANCER WITH SPLEISSOSOME MUTATIONS
WO2019199667A2 (en) * 2018-04-09 2019-10-17 Keaney Gregg F Certain pladienolide compounds and methods of use
MX2020012940A (es) 2018-06-01 2021-03-25 Eisai R&D Man Co Ltd Metodos de uso de moduladores de empalme.
JOP20200268A1 (ar) 2018-06-01 2020-10-26 Eisai R&D Man Co Ltd تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
IL262658A (en) * 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
JP6931860B2 (ja) * 2019-02-08 2021-09-08 株式会社Ｚｅｎｉｃｋ ｍＲＮＡ前駆体の解析方法、情報処理装置、コンピュータプログラム
US20220073971A1 (en) * 2019-02-08 2022-03-10 Zenick Corporation Method for analyzing mrna precursor, information processing apparatus, and computer program
WO2020264177A1 (en) * 2019-06-26 2020-12-30 Fred Hutchinson Cancer Research Center Methods and compositions comprising brd9 activating therapies for treating cancers and related disorders
CN111518805A (zh) * 2020-04-30 2020-08-11 北京航空航天大学 一种可用于抑制肿瘤增殖的非编码基因及其应用
ES2891182A1 (es) * 2020-07-14 2022-01-26 Servicio Andaluz De Salud Compuestos para el tratamiento del carcinoma hepatocelular
CN116507334A (zh) * 2020-11-04 2023-07-28 卫材R&D管理有限公司 骨髓增生异常综合征（mds）的生物标记物及其使用方法
KR20230104204A (ko) 2020-11-04 2023-07-07 에자이 알앤드디 매니지먼트 가부시키가이샤 골수이형성 증후군(mds)에 대한 바이오마커 및 이를 사용하는 방법
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
WO2023209074A1 (en) * 2022-04-28 2023-11-02 Institut National de la Santé et de la Recherche Médicale Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372431B1 (en) * 1999-11-19 2002-04-16 Incyte Genomics, Inc. Mammalian toxicological response markers
EP1268609B1 (fr) 2000-02-18 2006-05-17 Centelion Procede de preparation de polyalkylenimines fonctionnalises, compositions les contenant et leur utilisations
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
TWI311558B (en) 2001-02-01 2009-07-01 Mercian Corporatio Novel physiologically active substance
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
RU2338741C2 (ru) 2002-07-31 2008-11-20 Мершан Корпорейшн Новые физиологически активные вещества
JP4459051B2 (ja) 2002-07-31 2010-04-28 メルシャン株式会社 新規生理活性物質
JP4439401B2 (ja) 2002-11-29 2010-03-24 メルシャン株式会社 マクロライド系化合物の製造方法
EP1705247A4 (en) 2003-11-27 2008-08-20 Mercian Corp DNA ACCOMPANYING HYDROXYLATION OF A MAKROLIDE COMPOUND
CN1977046A (zh) 2004-07-20 2007-06-06 卫材R&D管理有限公司 编码参与普拉地内酯生物合成的多肽的dna
CN101282967B (zh) 2005-10-13 2011-01-26 卫材R&D管理有限公司 普拉二烯内酯b和普拉二烯内酯d的全合成
WO2008111464A1 (ja) * 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. スプライシング異常を指標とする抗ガン剤の作用検定方法
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives
US8519115B2 (en) 2008-08-14 2013-08-27 Nanostring Technologies, Inc. Stable nanoreporters
TW201204393A (en) * 2010-04-16 2012-02-01 Daiichi Sankyo Co Ltd Diagnostic agent and therapeutic agent of cancer
EP2776830B1 (en) * 2011-11-08 2018-05-09 Genomic Health, Inc. Method of predicting breast cancer prognosis
WO2013086464A1 (en) * 2011-12-07 2013-06-13 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
JP6057408B2 (ja) 2012-03-05 2017-01-11 国立大学法人 千葉大学 癌の予防剤および／または治療剤
US20140275010A1 (en) 2013-03-12 2014-09-18 Guo Zhu Zheng Quaternary salts
US10113201B2 (en) 2013-04-05 2018-10-30 The Wistar Institute Of Anatomy And Biology Methods and compositions for diagnosis of glioblastoma or a subtype thereof
UA119458C2 (uk) 2014-05-15 2019-06-25 Ейсей Р Енд Д Менеджмент Ко., Лтд. Сполуки піридину пладієноліду та способи застосування
ES2887201T3 (es) 2015-09-01 2021-12-22 Eisai R&D Man Co Ltd Variantes de empalme asociadas con mutantes neomórficos de SF3B1

Also Published As

Publication number Publication date
JP2018525994A (ja) 2018-09-13
EP3344780B1 (en) 2021-06-23
JP7256840B2 (ja) 2023-04-12
EP3910073A1 (en) 2021-11-17
EP3910073B1 (en) 2024-03-06
US20210130909A1 (en) 2021-05-06
JP2021106615A (ja) 2021-07-29
US10889866B2 (en) 2021-01-12
US20180318312A1 (en) 2018-11-08
EP3344780A2 (en) 2018-07-11
WO2017040526A3 (en) 2017-04-20
ES2887201T3 (es) 2021-12-22
WO2017040526A2 (en) 2017-03-09
US11761045B2 (en) 2023-09-19

Similar Documents

Publication Publication Date Title
JP6876680B2 (ja) ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント
JP5421374B2 (ja) 悪性神経膠腫におけるイソクエン酸デヒドロゲナーゼ遺伝子および他の遺伝子の遺伝子変化
Li et al. Cancer-associated fibroblasts foster a high-lactate microenvironment to drive perineural invasion in pancreatic cancer
JP7519125B2 (ja) 融合遺伝子及び／又はエクソンスキッピングにより生ずる転写産物を検出するためのプローブ及び方法
US20170198353A1 (en) Kras mutations and resistance to anti-egfr treatment
WO2017079632A1 (en) Patient-derived ctc-xenograft models
CN106434870A (zh) ncRNA及其用途
EP4182480B1 (en) Prognostic biomarkers for cancer
JP2006523456A (ja) 分子細胞遺伝学的方法を用いる癌連鎖遺伝子および治療標的の確認
CN114908171A (zh) 人HHIPL2 mRNA在非小细胞肺癌靶向治疗和预后评估中的应用及试剂盒
Zeng et al. MALAT1 promotes FOXA1 degradation by competitively binding to miR-216a-5p and enhancing neuroendocrine differentiation in prostate cancer
CN107148481A (zh) 用于确定患有braf‑阳性癌症的患者为braf抑制剂非响应者且为mapk/erk抑制剂响应者的工具和方法
KR20210144353A (ko) 단일세포 전사체 분석에 기반한 대장암의 예후 예측 방법
EP3464623B1 (en) Androgen receptor splice variants and androgen deprivation therapy
HK40063437B (en) Splice variants associated with neomorphic sf3b1 mutants
HK40063437A (en) Splice variants associated with neomorphic sf3b1 mutants
CN116287239B (zh) 用于诊断癌症的分子标志物、试剂盒及其应用
CN112795651B (zh) Muc20作为诊断多发性套细胞淋巴瘤蛋白酶体抑制剂耐药的标志物及其应用
KR101370108B1 (ko) 위암 진단용 마커로서 ｈｄａｃ2의 용도
Tüns High-throughput analyses for the identification of progression-specific factors in non-small-cell lung cancer
Lu et al. RPL34-Divergent Transcript, a Novel Long NonCoding Ribonucleic Acid, Promotes Migration by Activating Epithelial-Mesenchymal Transition in Glioma
WO2024196792A2 (en) Identification of selective regulators of oncogene translation
CN120536430A (zh) 一种分离的Circ_CIT基因序列、基于实时荧光定量PCR检测鼻咽癌相关基因表达水平的方法及试剂盒
Iiris et al. Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers
BG67180B1 (bg) Метод и кит за откриване на онкофузионен протеин

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201029

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210330

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210426

R150 Certificate of patent or registration of utility model

Ref document number: 6876680

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE

Ref document number: 6876680

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250